Does Anthem (Elevance Health) Cover Leqvio (Inclisiran)?

What Is Leqvio and Why Does Coverage Matter?

Leqvio (inclisiran) is a small-interfering RNA (siRNA) agent that silences hepatic PCSK9 synthesis, reducing LDL-C by roughly 50% from baseline with only two injections per year after the initial loading phase. The FDA approved inclisiran in December 2021 for adults with HeFH or established ASCVD who require additional LDL-C lowering on top of maximally tolerated statin therapy [1]. Because each dose costs approximately $3,400 at list price (translating to roughly $6,800 annually or about $540 per month amortized), insurer prior authorization is nearly universal, and Anthem (Elevance Health) is no exception [2].

The ORION-10 trial (N=1,561, NEJM 2020) demonstrated that inclisiran 284 mg reduced LDL-C by 52.3% at day 510 versus placebo (P<0.0001) in patients with established ASCVD already on statins [3]. The companion ORION-11 trial (N=1,617) showed a 49.9% reduction in patients with ASCVD or ASCVD risk equivalents including HeFH (P<0.0001) [3]. These trials formed the evidentiary core of the FDA submission and are the same trials Anthem's medical policy team references when evaluating PA requests.

Understanding Anthem's specific criteria before submitting a PA request saves weeks of back-and-forth. Incomplete requests are the single most common reason for avoidable denials, according to the ACC/AHA 2022 cholesterol guideline implementation guidance [4].

What Formulary Tier Is Leqvio on Anthem Plans?

Leqvio sits on the specialty tier, typically Tier 4 or Tier 5, on most Anthem commercial PPO and HMO formularies. Specialty tiers carry the highest member cost-sharing: coinsurance rates of 25% to 33% are common, sometimes with a separate specialty deductible that must be satisfied first [5].

Tier placement varies by the specific Anthem sub-plan. Anthem Blue Cross of California, Anthem Health Plans of Virginia, and the other regional Blue Cross Blue Shield licensees that operate under the Elevance Health corporate umbrella each maintain separate formularies. Always confirm the exact tier by entering inclisiran (or "Leqvio") into the drug search tool on your plan's member portal, or by calling the pharmacy benefits number on the back of your insurance card.

Medicare Advantage plans administered by Anthem follow CMS Part D formulary rules. CMS requires all Part D plans to cover at least two drugs in each therapeutic category, but PCSK9 inhibitor coverage remains restricted and often requires PA even when the drug is listed [6]. The 2023 Medicare Drug Price Negotiation Program did not include inclisiran in its first negotiation list, so Part D pricing currently reflects list price minus any manufacturer rebates [7].

What Are Anthem's Prior Authorization Criteria for Leqvio?

Anthem's PA criteria for Leqvio generally require all of the following: a confirmed diagnosis of HeFH (via genetic testing, clinical criteria, or a Dutch Lipid Clinic Network score) or documented established ASCVD such as prior MI, stroke, or peripheral artery disease; documented LDL-C above 70 mg/dL (or above 100 mg/dL for HeFH without clinical ASCVD) despite therapy; and evidence of maximally tolerated statin therapy for at least 90 days [8].

Step therapy is standard. Most Anthem commercial policies require prior trials of both a high-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) and at least one additional agent, most commonly ezetimibe 10 mg. Documented intolerance to statins, defined as myopathy, rhabdomyolysis, or at least two distinct statin trials resulting in discontinuation due to adverse effects, may waive the statin requirement but still requires ezetimibe or bempedoic acid documentation in most policy versions [9].

The prescribing clinician must hold a cardiology, endocrinology, or lipidology specialty designation or provide documentation of a specialist consultation. Primary care prescriptions without specialist involvement are frequently pended for additional clinical review [10].

PA approvals are typically granted for 12 months, then require re-authorization with updated LDL-C labs and documentation of ongoing clinical need. Anthem's standard PA processing time is 3 business days for non-urgent requests and 72 hours for urgent clinical situations under most state prompt-pay regulations [11].

The HealthRX Leqvio PA Submission Checklist for Anthem Plans

The following documentation package, assembled before the PA is submitted, addresses the most common reasons Anthem returns inclisiran requests as incomplete or issues a denial:

1. Diagnosis documentation: ICD-10 code E78.01 (pure hypercholesterolemia with HeFH) or relevant ASCVD code (I25.10, I63.x, etc.) plus supporting clinical notes.
2. LDL-C labs: Two results, ideally from the past 6 months, both above the plan's threshold, with dates and ordering provider.
3. Statin trial record: Pharmacy fill history or chart notes showing at least 90 continuous days of high-intensity statin at the guideline-recommended dose.
4. Ezetimibe or add-on agent trial: Fill history or chart note with dose, duration, and reason for inadequate response or intolerance.
5. Specialist note: A cardiology, endocrinology, or lipidology note from the past 12 months confirming the diagnosis and the need for PCSK9i class therapy.
6. Prescriber attestation: Signed statement that the patient is on maximally tolerated lipid-lowering therapy.
7. Letter of medical necessity: Tailored to Anthem's published clinical policy number for PCSK9 inhibitors (policy references vary by regional entity; verify the current policy number at anthem.com/provider).

Submitting all seven elements in the initial PA reduces the average approval cycle by an estimated 5 to 7 business days compared to piecemeal submission.

Does Anthem Require Step Therapy Before Leqvio?

Yes. Step therapy is the default requirement on most Anthem commercial plans before inclisiran will be authorized. The required steps generally follow the AHA/ACC 2018 cholesterol guideline's evidence hierarchy [12]: high-intensity statin first, ezetimibe second, and a PCSK9 inhibitor (either evolocumab, alirocumab, or inclisiran) third.

Some state laws limit step therapy duration. Virginia, for example, enacted step therapy reform legislation requiring insurers to grant exceptions within 72 hours when a clinician certifies that the required step therapy drug is clinically contraindicated or would cause adverse effects based on the patient's history [13]. California, New York, and Texas have enacted similar protections. Check your state's insurance commissioner website or have a patient advocate confirm applicable state law before accepting a step therapy denial as final.

When a patient has already failed evolocumab (Repatha) or alirocumab (Praluent), a documented trial of a prior PCSK9 inhibitor with suboptimal adherence (due to the biweekly injection burden) is a clinically valid argument for switching to inclisiran's biannual dosing. Including a brief clinical rationale in the letter of medical necessity explaining why inclisiran's twice-yearly dosing schedule directly addresses documented adherence barriers is often persuasive during clinical review [14].

The ACC's 2022 Expert Consensus Decision Pathway on PCSK9 inhibitor use states: "For patients in whom adherence to more frequent injection schedules has been problematic, inclisiran's twice-yearly maintenance dosing represents a clinically meaningful differentiation." This framing, cited directly in the appeal letter, gives the reviewing physician a peer-society anchor for approving the switch [15].

How Do I Appeal an Anthem Denial of Leqvio?

An Anthem denial is not final. Federal law under the Affordable Care Act and the Employee Retirement Income Security Act (ERISA) guarantees the right to at least one internal appeal and, for most plans, an external Independent Review Organization (IRO) review [16].

Step 1: Request the denial explanation. Anthem must provide a written explanation of the denial reason, the specific clinical criteria applied, and the name of the reviewing clinician within 5 business days of the adverse determination. Request this immediately if it is not provided with the denial letter.

Step 2: File the internal appeal within 180 days. The appeal letter should reference Anthem's published clinical policy by number, cite the ORION-10 and ORION-11 outcomes data [3], quote the ACC 2022 Expert Consensus [15], and include a detailed letter of medical necessity from the prescribing specialist. Attach updated LDL-C labs and any new cardiovascular events since the original PA was submitted.

Step 3: Request expedited review if clinically urgent. If the treating physician certifies that delay would seriously jeopardize the patient's health, Anthem must respond to the internal appeal within 72 hours [16].

Step 4: External IRO review. If the internal appeal is denied, the patient has the right to an independent external review. IRO decisions are binding on the insurer in most states. A 2021 analysis published in JAMA Internal Medicine found that external reviewers overturn insurer denials in approximately 39% to 41% of cases across specialty drug categories [17].

Step 5: State insurance commissioner complaint. Filing a complaint with the state insurance commissioner simultaneously with the IRO request adds regulatory pressure and creates a public record of the denial pattern. Anthem's compliance team is often more responsive when a commissioner complaint is open.

Patients who are acutely cardiovascular high-risk, such as those with a recent ACS or recurrent MI, qualify for expedited PA and expedited appeal timelines under most state and federal standards. Document this clinical urgency explicitly in every communication [18].

Can I Use the Novartis Savings Card with Anthem Coverage?

The Novartis LEQVIO Connect savings program reduces out-of-pocket costs for eligible commercially insured patients. Patients covered by Anthem commercial plans (not Medicare, Medicaid, or any federal program) may use the card to cap their copay, though the exact cap amount and eligibility conditions are set by Novartis and change periodically [19].

Federal law prohibits the use of manufacturer copay cards for patients enrolled in any government-funded program, including Medicare Part D, Medicaid, TRICARE, and VA benefits. Using a copay card under these circumstances is considered a False Claims Act violation, and providers and patients should avoid it entirely [20].

For patients who do not qualify for the Novartis card, the Leqvio Connect patient support program includes a dedicated case manager service that can assist with PA paperwork, appeal coordination, and, for qualifying low-income patients, free drug through Novartis' patient assistance program. Contact Novartis directly at 1-833-LEQVIO1 or through leqvio.com to initiate enrollment.

How Does Leqvio Compare to Other PCSK9 Inhibitors Under Anthem Coverage?

Evolocumab (Repatha) and alirocumab (Praluent) are both FDA-approved PCSK9 monoclonal antibodies with established Anthem coverage policies. Both are available as self-administered subcutaneous injections every two weeks (or monthly for some formulations), compared with inclisiran's biannual maintenance dosing after loading [21].

Efficacy is broadly comparable. The FOURIER trial (N=27,564) showed evolocumab reduced LDL-C by 59% from baseline at 48 weeks (P<0.001) and reduced major adverse cardiovascular events (MACE) by 15% versus placebo [22]. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced LDL-C by approximately 55% and MACE by 15% in post-ACS patients (P<0.001) [23]. Inclisiran has not yet completed a dedicated cardiovascular outcomes trial, though the ORION-4 trial (N=15,000+, ongoing) is expected to report MACE data [24].

Anthem may preferentially authorize evolocumab or alirocumab before inclisiran because both have MACE outcome data and longer formulary histories. Prescribers should anticipate this and, when the clinical preference is inclisiran specifically, address adherence advantages in the PA letter directly.

For patients who have already succeeded on evolocumab or alirocumab, switching to inclisiran purely for convenience does not typically meet Anthem's medical necessity threshold without additional clinical justification [25].

What Does the Evidence Say About Inclisiran's Safety Profile?

Safety data from the pooled ORION-10 and ORION-11 populations (combined N=3,178) showed that the most common adverse effect was injection-site reactions, occurring in 4.7% of inclisiran-treated patients versus 0.5% of placebo patients [3]. Serious adverse event rates were similar between groups (24.5% inclisiran versus 24.8% placebo), and no cases of neurocognitive adverse effects attributable to LDL-C lowering were identified at the doses studied [3].

The FDA label carries no boxed warning [1]. Liver function monitoring is not required, differentiating inclisiran from older lipid-modifying agents such as niacin or fibrates. No dose adjustment is required for mild to moderate renal impairment, though data in severe renal impairment (eGFR <30 mL/min/1.73 m²) are limited [1].

Pregnancy is a contraindication. LDL-C is necessary for fetal development, and PCSK9 inhibitors as a class are not recommended during pregnancy or breastfeeding per current ACC/AHA guidance [4]. Anthem's PA criteria universally exclude pregnant patients from PCSK9i authorization.

Who Is the Ideal Candidate for Leqvio Under Anthem Coverage?

The patients most likely to receive Anthem PA approval for inclisiran share a specific clinical profile: documented HeFH or established ASCVD, LDL-C persistently above 70 mg/dL despite high-intensity rosuvastatin or atorvastatin plus ezetimibe for at least 90 days, and a recent cardiovascular event or high-burden atherosclerosis documented by imaging [26].

Patients with statin intolerance documented across two separate statin trials at any dose, combined with inadequate LDL-C reduction on ezetimibe alone, also meet the threshold in most Anthem regional policies. Bempedoic acid (Nexletol) as a documented step-therapy agent is increasingly acceptable in lieu of statin documentation under Anthem's 2024 policy revisions in several states [9].

The AHA's 2022 Science Advisory on PCSK9 inhibitor underutilization noted that "fewer than 5% of patients who meet guideline criteria for PCSK9 inhibitor therapy currently receive a prescription," attributing this gap primarily to insurer barriers, including PA burden and step therapy requirements [27]. Addressing those barriers systematically, starting with the documentation checklist above, is the most direct way to convert a guideline-eligible patient into an approved one.

Patients with LDL-C above 190 mg/dL at baseline, even without established ASCVD, may qualify under HeFH criteria per the ACC/AHA 2018 guideline, which assigns a Class IIa recommendation for PCSK9 inhibitors when LDL-C remains above 100 mg/dL after maximally tolerated statin plus ezetimibe in HeFH patients [12]. Anthem's policies in most regions mirror this threshold.